{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T18:46:25Z","timestamp":1787942785845,"version":"build-2784847793"},"reference-count":13,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2023,3,31]],"date-time":"2023-03-31T00:00:00Z","timestamp":1680220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Hosp Pharm"],"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:p>Purpose: Neutropenia is an uncommon adverse effect associated with prolonged vancomycin therapy. Methods: This was a case report on a 62-year-old African American male with hypertension, paranoid schizophrenia, and a history of polysubstance abuse developed foot osteomyelitis. The patient was initially maintained on intravenous Vancomycin &amp; Ceftriaxone for ~3 weeks but adjusted to Daptomycin &amp; Ceftriaxone while in hospital due to neutropenia. Patient\u2019s neutropenia quickly resolved once discontinuation of Vancomycin occurred. Results: Vancomycin is a potential cause of drug induced leukopenia and neutropenia. Monitoring of leukocytes and neutrophils is warranted in patients receiving long term intravenous Vancomycin therapy. Conclusion: Vancomycin is a bactericidal glycopeptide antibiotic with activity against gram-positive organisms such as Staphylococci. Well-known adverse drug events include nephrotoxicity and ototoxicity. Vancomycin-induced neutropenia on the other hand is less common and reported at lower rates. It is defined as an ANC less than 1000 \u00b5L in patients maintained on Vancomycin infusions. According to Black et al, neutropenia is more likely associated with prolonged therapy; generally occurring at least 20 days after initiation.<\/jats:p>","DOI":"10.1177\/00185787231158775","type":"journal-article","created":{"date-parts":[[2023,3,31]],"date-time":"2023-03-31T07:00:57Z","timestamp":1680246057000},"page":"441-443","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":4,"title":["Vancomycin-Induced Leukopenia and Neutropenia: Time Will Tell"],"prefix":"10.1177","volume":"58","author":[{"given":"Nam","family":"Nguyen","sequence":"first","affiliation":[{"name":"Xavier University of Louisiana College of Pharmacy, New Orleans, LA, USA"},{"name":"Southeast Louisiana Veterans Health Care System, New Orleans, LA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1140-8813","authenticated-orcid":false,"given":"Ahlam","family":"Ayyad","sequence":"additional","affiliation":[{"name":"Xavier University of Louisiana College of Pharmacy, New Orleans, LA, USA"},{"name":"Southeast Louisiana Veterans Health Care System, New Orleans, LA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2023,3,31]]},"reference":[{"key":"bibr1-00185787231158775","volume-title":"Casebook in Clinical Pharmacokinetics and Drug Dosing","author":"Riccobono DE","year":"2015"},{"key":"bibr2-00185787231158775","doi-asserted-by":"publisher","DOI":"10.1177\/0004867418821441"},{"key":"bibr3-00185787231158775","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2010.09.018"},{"key":"bibr4-00185787231158775","doi-asserted-by":"publisher","DOI":"10.1177\/0004867412460594"},{"key":"bibr5-00185787231158775","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-021-03073-w"},{"key":"bibr6-00185787231158775","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkq339"},{"key":"bibr7-00185787231158775","first-page":"002215","volume":"8","author":"Couto L","year":"2021","journal-title":"Eur J Case Rep Intern Med"},{"key":"bibr8-00185787231158775","doi-asserted-by":"publisher","DOI":"10.1155\/2009\/495863"},{"key":"bibr9-00185787231158775","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1P583"},{"key":"bibr10-00185787231158775","doi-asserted-by":"publisher","DOI":"10.4172\/2332-0877.1000336"},{"key":"bibr11-00185787231158775","doi-asserted-by":"publisher","DOI":"10.1592\/phco.22.9.783.34059"},{"key":"bibr12-00185787231158775","doi-asserted-by":"publisher","DOI":"10.1592\/phco.19.3.240.30912"},{"key":"bibr13-00185787231158775","unstructured":"LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. National Institute of Diabetes and Digestive and Kidney Diseases; 2012. Adverse Drug Reaction Probability Scale (Naranjo) in Drug Induced Liver Injury. Updated May 4, 2019. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK548069\/"}],"container-title":["Hospital Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/00185787231158775","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/00185787231158775","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/00185787231158775","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T08:40:11Z","timestamp":1777452011000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/00185787231158775"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,31]]},"references-count":13,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["10.1177\/00185787231158775"],"URL":"https:\/\/doi.org\/10.1177\/00185787231158775","relation":{},"ISSN":["0018-5787","1945-1253"],"issn-type":[{"value":"0018-5787","type":"print"},{"value":"1945-1253","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,31]]}}}